SYN 116Alternative Names: SYN116
Latest Information Update: 02 Mar 2017
At a glance
- Originator Roche
- Developer Biotie Therapies Corp.
- Class Analgesics
- Mechanism of Action Prostaglandin I2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 29 Mar 2011 Discontinued - Phase-I for Pain in USA (PO)
- 01 Feb 2011 Synosia Therapeutics has been acquired by Biotie
- 12 Mar 2009 Phase-I development is ongoing for Pain